The role of pharmacokinetic (PK) modeling and simulations in selecting anti-SEMA4D antibody dose for phase I study in patients with advanced malignancies.
A. F. Nasser
No relevant relationships to disclose
B. Budda
Consultant or Advisory Role - Balasubrahmanyam Budda (U)
C. A. Cornelius
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
T. Fisher
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
L. A. Winter
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
J. E. Leonard
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex